Literature DB >> 18039093

Endometrial carcinoma.

Antonio Di Cristofano1, Lora Hedrick Ellenson.   

Abstract

Endometrial carcinoma, a common malignancy of the female genital tract, is composed of a number of tumor types with different light-microscopic features, molecular genetic alterations, and prognoses. In addition, hormonal influences significantly impact growth regulatory pathways and interact with genetic alterations in the pathogenesis of at least some types of endometrial carcinoma. These factors have complicated the analyses of endometrial carcinoma, but over the past decades, awareness of the different types of endometrial carcinoma, in addition to careful clinicopathological studies, molecular analyses, and animal studies of the biological underpinnings of the different tumor types, has increased. We present the current understanding of endometrial carcinoma, from a molecular vantage point, highlighting what are presently thought to be the fundamental pathways involved in the development and progression of the major types of endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039093     DOI: 10.1146/annurev.pathol.2.010506.091905

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  101 in total

1.  Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.

Authors:  Elisabetta Kuhn; Alan Meeker; Tian-Li Wang; Ann Smith Sehdev; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

2.  Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.

Authors:  Henry D Reyes; Matthew J Carlson; Eric J Devor; Yuping Zhang; Kristina W Thiel; Megan I Samuelson; Megan McDonald; Shujie Yang; Jean-Marie Stephan; Erica C Savage; Donghai Dai; Michael J Goodheart; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2015-10-30       Impact factor: 5.482

3.  Neutrophils Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells.

Authors:  Adam Blaisdell; Amandine Crequer; Devin Columbus; Takiko Daikoku; Khush Mittal; Sudhansu K Dey; Adrian Erlebacher
Journal:  Cancer Cell       Date:  2015-12-14       Impact factor: 31.743

Review 4.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

5.  beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus.

Authors:  J-W Jeong; H S Lee; H L Franco; R R Broaddus; M M Taketo; S Y Tsai; J P Lydon; F J DeMayo
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

Review 6.  Endometrial regeneration and endometrial stem/progenitor cells.

Authors:  Caroline E Gargett; Hong P T Nguyen; Louie Ye
Journal:  Rev Endocr Metab Disord       Date:  2012-12       Impact factor: 6.514

7.  Molecular profiling of endometrial malignancies.

Authors:  Norasate Samarnthai; Kevin Hall; I-Tien Yeh
Journal:  Obstet Gynecol Int       Date:  2010-03-28

8.  Fibulin-5 localisation in human endometrial cancer shifts from epithelial to stromal with increasing tumour grade, and silencing promotes endometrial epithelial cancer cell proliferation.

Authors:  Amy Louise Winship; Kate Rainczuk; Amanda Ton; Eva Dimitriadis
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

9.  Down-regulated expression of Notch signaling molecules in human endometrial cancer.

Authors:  Violeta Jonusiene; Ausra Sasnauskiene; Nadezda Lachej; Daiva Kanopiene; Daiva Dabkeviciene; Sofija Sasnauskiene; Birute Kazbariene; Janina Didziapetriene
Journal:  Med Oncol       Date:  2013-01-13       Impact factor: 3.064

10.  The Synergistic Effect of Conditional Pten Loss and Oncogenic K-ras Mutation on Endometrial Cancer Development Occurs via Decreased Progesterone Receptor Action.

Authors:  Tae Hoon Kim; Jinrong Wang; Kevin Y Lee; Heather L Franco; Russell R Broaddus; John P Lydon; Jae-Wook Jeong; Francesco J Demayo
Journal:  J Oncol       Date:  2009-10-27       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.